ArticleZoological research2026
miR-449a modulates Alzheimer's disease pathology through regulation of Navβ2.
Article in Zoological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression of Alzheimer's disease (AD) from mild cognitive impairment (MCI) to dementia occurs gradually and remains mechanistically unresolved, limiting development of effective interventions. This study investigated the contribution of Navβ2 and its upstream regulatory microRNA, miR-449a, to MCI- and AD-associated neuropathology in multiple mouse models. Results revealed that Navβ2 expression was dysregulated in MCI and AD mice, accompanied by synaptic abnormalities, aberrant amyloid precursor protein (APP) processing, and disrupted Nav1.1α expression. Importantly, manipulation of miR-449a markedly influenced synaptic function and cognition through regulation of Navβ2, with miR-449a overexpression alleviating and miR-449a inhibition exacerbating cognitive impairment. Co-transfection assays further demonstrated that the effects of miR-449a on APP metabolism were mediated by Navβ2. Electrophysiological analyses provided additional evidence that the miR-449a/Navβ2 axis participates in regulation of cognitive function. Together, these findings provide new mechanistic insight into synaptic dysfunction and cognitive decline in AD and identify the miR-449a/Navβ2 axis as a candidate therapeutic target for cognitive impairment. Further investigation of the miR-449a/Navβ2 axis may facilitate development of targeted strategies to preserve synaptic integrity and cognitive function during AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.